ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib (see Figure 3), approved by the FDA in 2001, is the first generation BCR-ABL inhibitor that inhibits proliferation of myeloid cells containing the BCR-ABL oncogene and is used in patients with chronic myeloid leukemia (CML).